Cargando…
P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428799/ http://dx.doi.org/10.1097/01.HS9.0000969600.16797.00 |
_version_ | 1785090556790046720 |
---|---|
author | Le Coutre, Philipp Göthert, Joachim Saussele, Susanne Pelzer, Uwe Bullinger, Lars Elmaagacli, Ahmet Jehn, Christian Stegelmann, Frank Hochhaus, Andreas Ernst, Thomas Burchert, Andreas |
author_facet | Le Coutre, Philipp Göthert, Joachim Saussele, Susanne Pelzer, Uwe Bullinger, Lars Elmaagacli, Ahmet Jehn, Christian Stegelmann, Frank Hochhaus, Andreas Ernst, Thomas Burchert, Andreas |
author_sort | Le Coutre, Philipp |
collection | PubMed |
description | |
format | Online Article Text |
id | pubmed-10428799 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-104287992023-08-17 P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL Le Coutre, Philipp Göthert, Joachim Saussele, Susanne Pelzer, Uwe Bullinger, Lars Elmaagacli, Ahmet Jehn, Christian Stegelmann, Frank Hochhaus, Andreas Ernst, Thomas Burchert, Andreas Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10428799/ http://dx.doi.org/10.1097/01.HS9.0000969600.16797.00 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
spellingShingle | Posters Le Coutre, Philipp Göthert, Joachim Saussele, Susanne Pelzer, Uwe Bullinger, Lars Elmaagacli, Ahmet Jehn, Christian Stegelmann, Frank Hochhaus, Andreas Ernst, Thomas Burchert, Andreas P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL |
title | P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL |
title_full | P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL |
title_fullStr | P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL |
title_full_unstemmed | P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL |
title_short | P674: 2ND-LINE PONATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) PATIENTS FAILING OR INTOLERANT TO 1ST-LINE 2ND GENERATION TKI THERAPY: INTERIM ANALYSIS OF THE PROSPECTIVE PONS TRIAL |
title_sort | p674: 2nd-line ponatinib in chronic phase chronic myeloid leukemia (cml-cp) patients failing or intolerant to 1st-line 2nd generation tki therapy: interim analysis of the prospective pons trial |
topic | Posters |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428799/ http://dx.doi.org/10.1097/01.HS9.0000969600.16797.00 |
work_keys_str_mv | AT lecoutrephilipp p6742ndlineponatinibinchronicphasechronicmyeloidleukemiacmlcppatientsfailingorintolerantto1stline2ndgenerationtkitherapyinterimanalysisoftheprospectiveponstrial AT gothertjoachim p6742ndlineponatinibinchronicphasechronicmyeloidleukemiacmlcppatientsfailingorintolerantto1stline2ndgenerationtkitherapyinterimanalysisoftheprospectiveponstrial AT sausselesusanne p6742ndlineponatinibinchronicphasechronicmyeloidleukemiacmlcppatientsfailingorintolerantto1stline2ndgenerationtkitherapyinterimanalysisoftheprospectiveponstrial AT pelzeruwe p6742ndlineponatinibinchronicphasechronicmyeloidleukemiacmlcppatientsfailingorintolerantto1stline2ndgenerationtkitherapyinterimanalysisoftheprospectiveponstrial AT bullingerlars p6742ndlineponatinibinchronicphasechronicmyeloidleukemiacmlcppatientsfailingorintolerantto1stline2ndgenerationtkitherapyinterimanalysisoftheprospectiveponstrial AT elmaagacliahmet p6742ndlineponatinibinchronicphasechronicmyeloidleukemiacmlcppatientsfailingorintolerantto1stline2ndgenerationtkitherapyinterimanalysisoftheprospectiveponstrial AT jehnchristian p6742ndlineponatinibinchronicphasechronicmyeloidleukemiacmlcppatientsfailingorintolerantto1stline2ndgenerationtkitherapyinterimanalysisoftheprospectiveponstrial AT stegelmannfrank p6742ndlineponatinibinchronicphasechronicmyeloidleukemiacmlcppatientsfailingorintolerantto1stline2ndgenerationtkitherapyinterimanalysisoftheprospectiveponstrial AT hochhausandreas p6742ndlineponatinibinchronicphasechronicmyeloidleukemiacmlcppatientsfailingorintolerantto1stline2ndgenerationtkitherapyinterimanalysisoftheprospectiveponstrial AT ernstthomas p6742ndlineponatinibinchronicphasechronicmyeloidleukemiacmlcppatientsfailingorintolerantto1stline2ndgenerationtkitherapyinterimanalysisoftheprospectiveponstrial AT burchertandreas p6742ndlineponatinibinchronicphasechronicmyeloidleukemiacmlcppatientsfailingorintolerantto1stline2ndgenerationtkitherapyinterimanalysisoftheprospectiveponstrial |